Stocks-2 News

Home Depot Q3 Earnings: Doing The Best It Can Against All Odds

Home Depot's Q3 performance exceeded expectations, driven by hurricane-related sales and the integration of SRS Distribution, leading to an upward revision of FY24 guidance. Despite positive Q3 results, high interest rates and elevated mortgage rates continue to defer larger remodeling projects, posing a significant headwind for Home Depot's growth. The SRS acquisition appears promising, contributing significantly to sales and aligning with Home Depot's strategy to emphasize the Pro segment, though its full impact will take time.

Befesa: Double-Digit EBITDA Growth In 2025, But Share Price Continues To Slide

Despite early investment missteps, I remain confident in Befesa's potential and have increased my position size, anticipating a recovery in EBITDA and net profit. Befesa's Q3 results show a 64% increase in operating profit, and the 2024 guidance suggests a strong Q4 and promising 2025 outlook. The company expects to reduce its debt ratio to 3 by year-end and to 2.5 by end of 2025, aligning with long-term goals.

November's 5 Dividend Growth Stocks With 4.91%+ Yields

Every month we screen for potential dividend growth opportunities, which can provide some new potential ideas that could otherwise slip by. While we look for more consistent dividend growers with relatively higher yields, we also include safety in terms of earnings stability or growth potential in the screening process. We look at five of those that screen the highest based on yield, and this month, we have two new names that haven't made the discussion portion before.

SMIG: Solid Exposure To Small And Mid-Cap Holdings

I'm a huge fan of the Bahl & Gaynor Small/Mid Cap Income Growth ETF, which combines small/mid-cap focus with dividend growth. SMIG's actively managed approach targets top-notch small and mid-cap companies with lasting competitive edges and strong income growth potential. The fund's concentrated portfolio and sector allocation in Industrials and Financials aim for steady dividends and capital appreciation.

Medical services provider CareMax files for Chapter 11 restructuring

CareMax , which operates 56 medical centers in Florida, Texas, Tennessee and New York catering largely to older patients, filed for Chapter 11 bankruptcy in Texas on Sunday.

Top Marijuana Stocks to Watch for Explosive Growth Opportunities

The US cannabis industry continues to show resilience, with steady growth despite recent challenges. The industry is valued at approximately $30 billion and is projected to exceed $50 billion by 2030. Recent pullbacks in marijuana stocks created opportunities for investors, especially as some stocks have rebounded with notable upside. Headlines regarding federal legalization efforts, including bipartisan discussions about the SAFE Banking Act, have added momentum. These developments fuel optimism for broader regulatory reform. Investors are now closely monitoring stocks with strong fundamentals and market positions. Proper research using technical analysis can help identify entry points. Moreover, understanding support and resistance levels and price trends is crucial for informed decision-making.

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases

The Schall Law Firm Urges Stockholder Participation In A Fraud Case Against Elanco Animal Health Incorporated

LOS ANGELES, CA / ACCESSWIRE / November 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE: ELAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 7, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before December 6, 2024.

Atlas Copco Is Perpetually Overvalued - A Q3'24 Wrap-Up

Atlas Copco is a high-quality, fundamentally sound company but is currently overvalued, trading at a premium of over 30x P/E. Despite a solid business model and high-value customers, the company's valuation remains too high for an attractive investment. I recommend a "Hold" rating, with an ideal entry point at 120 SEK/share, offering a realistic upside based on earnings growth.

ROSEN, A GLOBALLY RESPECTED INVESTOR RIGHTS FIRM, Encourages Lilium N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LILM, LILMF

NEW YORK, Nov. 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Lilium N.V. (NASDAQ: LILM) (OTC: LILMF) between June 11, 2024 and November 3, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 6, 2025.

Aviation Specialist Kratos Notches 4th Straight Profit. Is This Defense Stock Unstoppable Now?

Aviation Specialist Kratos Notches 4th Straight Profit. Is This Defense Stock Unstoppable Now?

Energy Stocks Have Soared This Year, but, These 3 Still Look Like Great Buys

Energy Stocks Have Soared This Year, but, These 3 Still Look Like Great Buys

Power Corporation of Canada: Undervalued With Strong Long-Term Growth Potential

I've maintained a 'buy' rating on Power Corporation of Canada due to its compelling valuation and 21% discount to NAV, offering significant value. The stock's 23.7% total return since March 2024, driven by a 20.1% share price rise and $0.56 quarterly dividend, outperformed the S&P 500 by nearly 12%. Despite a Q3'24 EPS miss and a 5% share price drop, the company's strong portfolio and shareholder returns through dividends and buybacks remain attractive.

Class Action Filed Against Edwards Lifesciences Corporation (EW) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / November 17, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=112265&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 13, 2025 in PACS Group, Inc. Lawsuit - PACS

NEW YORK, NY / ACCESSWIRE / November 17, 2024 / If you suffered a loss on your PACS Group, Inc. (NYSE:PACS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacs-group-inc-lawsuit-submission-form?prid=112263&wire=1 or contact Joseph E. Levi, Esq.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zeta Global Holdings Corp. (ZETA) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zeta Global Holdings Corp. ("Zeta" or "the Company") (NYSE:ZETA). Investors who purchased Zeta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZETA.

Quanterix Corporation (QTRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Huntington Ingalls Industries, Inc. (HII) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Huntington Ingalls Industries, Inc. ("Huntington Ingalls" or "the Company") (NYSE:HII). Investors who purchased Huntington Ingalls securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HII.

The Bancorp, Inc. (TBBK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Bancorp, Inc. ("Bancorp" or "the Company") (NASDAQ:TBBK). Investors who purchased Bancorp securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TBBK.

Delta Air Lines: Just The Start

Delta Air Lines is finally trading above pre-Covid levels, overcoming the July IT outage. Cruise lines and other industrial transport stocks still trade at higher valuation multiples, suggesting the airline rally is only getting started. DAL stock trades below 9x '25 EPS targets, still offering a cheap value.